Closure of Oroantral Fistula (OAF) Using Platelet Rich Fibrin With Middle Meatal Antrostomy

Outpatient Clinic of Alexandria University Teaching Hospital, Egypt

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06281873

Enrollment

Registered

2024-02-28

Start date

2023-03-27

Completion date

2024-02-07

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oroantral Fistula

Brief summary

the study evaluated the one stage endoscopic middle meatal antrostomy (EMMA) technique with the application of a platelet rich fibrin membrane (PRF) for Oroantral Fistula (OAF) closure and relief of maxillary sinusitis.

Detailed description

This study was conducted on nine eligible patients who complained of OAF with odontogenic sinusitis. Oral fistulectomy was done with proper curettage. Then, EMMA was performed with simultaneous closure of the OAF by application of PRF membrane and covering it with an acrylic splint. Patients were clinically evaluated for closure of the OAF after 14th days postoperatively, relief of the symptoms, and assessment of the pain level. Also, measurement of the size of the bone defect with the aid of computed tomography (CT) preoperatively and 24th weeks postoperatively.

Interventions

PROCEDUREclosure by PRF membrane

Oral fistulectomy was done with proper curettage. EMMA was performed. closure of the OAF by application of PRF membrane and covering it with an acrylic splint

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

20 Years to 60 Years

Healthy volunteers

Yes

Inclusion criteria

1 - Adult patients between the ages of 20-60 years. 2- Patients who were suffering from chronic fistula that occurred after the extraction of upper posterior teeth

Exclusion criteria

1. patients who have any systemic disease that contraindicates any intervention under general anesthesia (e.g., coronary artery disease). 2. OAF that occurred as a result of other causes (e.g., cyst,and trauma)

Design outcomes

Primary

Measure	Time frame	Description
Evaluation of the soft tissue wound's healing	1st, 7th, and14 days postoperatively	closure of the fistula using the Clinical Healing Score (CHS). CHS: score ranging from 0-5

Secondary

Measure	Time frame	Description
Secondary radiographic outcomes, assessment of bone formation	24 weeks postoperatively	Measurement of the size of the defect with CT size measured by millimeters (mm)

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026